Simultaneously analyzes thousands of naturally occurring and genetically engineered signal peptides
Significant improvements in protein yield (up to 500% in external validations)
Especially powerful for difficult-to-express proteins that hinder development
Compatible with expression optimization of any mammalian protein production system: from mRNA therapies to synthetic proteins
October 22, 2024
Avenue Biosciences Raises $2.5M Seed to Scale AI-Enhanced Protein Engineering
October 7, 2024
Avenue Biosciences Welcomes Industry Experts to Advisory Board for Market Insights and Focused Growth
October 4, 2024
Avenue Biosciences Joins StartX, the Largest Community of Stanford Founders
Our platform is a unique combination of high-throughput chemistry and synthetic biology, powered by machine learning and AI algorithms.
It is the most powerful solution to engineering N-terminal signal peptides: An element significantly underutilized in protein biologics.
Enhance any protein production system: From protein biologics and biosimilars to any mammalian protein-based biotechnology tools.
ENABLE PRODUCTION OF DIFFICULT-TO-EXPRESS PROTEINS
ENHANCE PROTEIN, mRNA & VIRAL THERAPIES
SINGLE CHAIN PROTEIN EXPRESSION OPTIMIZATION
MULTI-CHAIN PROTEIN EXPRESSION OPTIMIZATION (mABS, ANTIBODIES)
BOOSTING VACCINE & DRUG DISCOVERY
MAMMALIAN CELL LINE DEVELOPMENT
Increase the success of therapeutic and biotechnology development with precise, scalable protein engineering
Reduce time-to-market and production costs in pre-clinical therapeutic development
Gain a critical advantage and unique IP with novel molecular components